Summary by Moomoo AI
On January 8, 2024, Ardelyx, Inc. reported unaudited financial results for the fourth quarter and full year ended December 31, 2023. The company disclosed U.S. net product sales revenue of approximately $28 million for IBSRELA (tenapanor) in the fourth quarter, and around $80 million for the entire year. Additionally, Ardelyx announced unaudited U.S. net product sales revenue for XPHOZAH (tenapanor) of approximately $2.5 million for the same quarter. The preliminary report also included that the company had about $184 million in cash, cash equivalents, and short-term investments as of the year-end. These figures are subject to adjustments as they are part of the preparation for audited financial statements and may materially differ from the final amounts reported in the company's financial statements for the year.